Fulcover Mechanism of Action

Pharmacology: Pharmacodynamics: Itraconazole is a substituted triazole antimycotic agent with a broad spectrum of activity that includes Candida spp and other yeasts, dermatophytes and some other pathogenic fungi. It acts by impairing the synthesis of ergosterol in fungal cell membranes.
Pharmacokinetics: Peak plasma concentrations of Itraconazole in the region of 1 mcg equiv/ml are reached 1.5-3 hrs after administration. In man the elimination half life is about 20 hrs. Oral intake immediately after a meal doubled the peak level 3-4 hrs after intake. Peak concentrations of Itraconazole in keratinous tissues, especially skin, are up to 3 times higher than in plasma. Therapeutic levels in the skin persist for up to 2-4 weeks after stopping treatment as elimination is related to epidermal regeneration, rather than redistribution into the systemic circulation. Itraconazole is extensively metabolised by the liver to a large number of metabolites, which constitute 40% of the excreted dose. Faecal excretion of parent drug varies from 3-18% of the dose, and urinary excretion of unchanged drug is less than 0.03%.